A Phase IA/IB, Open Label, Multicenter, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.

Inclusion Criteria: - Life expectancy at least 12 weeks - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1 - Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy - Tumor Specimen availability Exclusion Criteria: - Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment - Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment - Active hepatitis B or C or tuberculosis - Positive test for human immunodeficiency virus (HIV) infection - Acute or chronic active Epstein-Barr virus (EBV) infection at screening - Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion - Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases - Active or history of autoimmune disease - Prior allogeneic stem cell or organ transplantation